The study established a mouse itch model induced by acute opioid and non-opioid pruritogens. The effects and mechanism of partial opioid agonist thienorphine on acute scratching behavior caused by opioid and non-opioid pruritogens was demonstrated. The noninvasive scratching behavior analysis system was established to test scratching behavior induced by morphine, bombesin, 5-hydroxytryptamine (5-HT) or chloroquine in C57 BL/6J mice. The effect of thienorphine (0.75, 1.5, 3 mg·kg^-1) on acute itch caused by above pruritogens were studied. The expression of protein kinase C δ (PKC δ) in mouse spinal cord was detected by Western blot after pruritogens addition with or without thienorphine pretreatment. All operations in the experiment were approved by the Institutional Animal Care and Use Committee of the Academy of Military Medical Sciences (IACUC-2021-017W). The scratching behavior increased significantly under morphine (1 nmol, i.t), bombesin (0.3 nmol, i.t), 5-HT (5 nmol, i.d) or chloroquine (20 nmol, i.d) treatment, respectively. Thienorphine (1.5 mg·kg^-1) significantly inhibited the scratching behavior induced by the morphine, bombesin, 5-HT and chloroquine. Thienorphine significantly reversed the changes in PKC δ protein expression induced by morphine or 5-HT. In conclusion, the partial opioid agonist thienorphine could inhibit scratching behavior induced by opioid and non-opioid pruritogens. It might reverse PKC δ through different pathways to inhibit opioids and non-opioids induced scratching behavior, which provided a new idea for exploring and treating itch.